Position in HYPMY
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$58,246
New position
Shares Held
13,390
first reported quarter
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1
of 1 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026RHUMBLINE ADVISERS holds $438,094,582 across 50 Drug Manufacturers - Specialty & Generic names. HYPMY ranks #44 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
1,229,009 | $145,281,153 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
122,486 | $72,631,748 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
303,820 | $40,025,246 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
1,268,203 | $30,348,097 | |
| 5 | VTRS |
Viatris Inc
|
1,941,082 | $26,224,017 | |
| 6 | ALKS |
Alkermes plc.
|
449,531 | $15,895,416 | |
| 7 | LNTH |
Lantheus Holdings, Inc.
|
194,563 | $14,757,603 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
643,856 | $13,366,450 |
All Filings in HYPMY
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $58,246 | 13,390 | Shares | Sole | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||